Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Factors contributing to retroviral integration have been intractable because past studies have not precisely located genomic sites of proviruses in sufficient numbers for significant analysis. In this study, 903 murine leukemia virus (MLV) and 379 human immunodeficiency virus–1 (HIV-1) integrations in the human genome were mapped. The data showed that MLV preferred integration near the start of transcriptional units (either upstream or downstream) whereas HIV-1 preferred integration anywhere in the transcriptional unit but not upstream of the transcriptional start. Defining different integration site preferences for retroviruses will have important ramifications for gene therapy and may aid in our understanding of the factors directing the integration process.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The well-understood integration preferences of HIV-1 for active transcription units72 and MLV for promoter/enhancer regions73–75 are in large part dictated via specific interactions of the respective IN proteins with chromatin-bound host factors.”
From Structure and function of retroviral integrase (2022) · cites this paper as [73]
In the citing paper
“Multiple studies now indicate that gammaretroviral vectors such as the vectors used in the two SCID-X1 trials preferentially integrate into the 5′ end of genes, near the transcription start sites[47].”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [47]
In the citing paper
“Finally, the preferred sequences of the genome for integration are different from the γ-RVV, with LVV preferentially integrating in genes and introns away for transcriptional start sites preferred by γ-RVV.20”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [20]
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.-P., Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012616 · Cited by 1,058
CpG islands as gene markers in the human genome
Larsen, F., Gundersen, G., Lopez, R., & Prydz, H. (1992) · Genomics · doi:10.1016/0888-7543(92)90024-m · Cited by 922
Pryciak, P. M., & Varmus, H. E. (1992) · Cell · doi:10.1016/0092-8674(92)90289-o · Cited by 273
Introducing RefSeq and LocusLink: curated human genome resources at the NCBI
Pruitt, K. D., Katz, K. S., Sicotte, H., & Maglott, D. R. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01882-x · Cited by 241
Check, E. (2002) · Nature · doi:10.1038/420116a · Cited by 238
Pruss, D., Bushman, F. D., & Wolffe, A. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.5913 · Cited by 236
Transcriptionally active genome regions are preferred targets for retrovirus integration
Scherdin, U., Rhodes, K., & Breindl, M. (1990) · Journal of Virology · doi:10.1128/jvi.64.2.907-912.1990 · Cited by 210
Research works printed but not linked: 2
- National Center for Biotechnology Information Reference Sequence Project (RefSeq) www.ncbi.nlm.nih.gov/RefSeq/.
- The database is available online at www.ncbi.nlm.nih.gov/geo/.
Cited by
Items 701–800 of 1,000
Uchida, N., Hanawa, H., Dan, K., Inokuchi, K., & Shimada, T. (2009) · Journal of Nippon Medical School · doi:10.1272/jnms.76.134 · Cited by 20
Majumdar, A., Chatterjee, A. G., Ripmaster, T. L., & Levin, H. L. (2011) · Journal of Virology · doi:10.1128/jvi.01719-10 · Cited by 19
“Human immunodeficiency virus type 1 (HIV-1) integrates with a bias in favor of genes that are actively transcribed by polymerase II (Pol II) (34, 37).”
BackgroundGene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa
Perdoni, C., Osborn, M. J., & Tolar, J. (2015) · Translational research · doi:10.1016/j.trsl.2015.05.008 · Cited by 29
“Furthermore, both RVs and LVs show a bias toward integrating into transcriptionally active regions of the genome.(47) These factors raise significant concerns for adverse events related to insertional mutagenesis, which have been documented in previous RV gene therapy trials that resulted in vector-induced leukemogene…”
BackgroundRetroviral integrase: Structure, mechanism, and inhibition
Passos, D. O., Li, M., Craigie, R., & Lyumkis, D. (2021) · The Enzymes · doi:10.1016/bs.enz.2021.06.007 · Cited by 22
“The association of BET proteins with gamma-retroviral IN provided mechanistic explanation to earlier observations that integration occurs preferentially within transcription start sites and upstream promoter regions [132].”
BackgroundResultHayakawa, J., Washington, K. N., Uchida, N., Phang, O. A., Kang, E. M., Hsieh, M. M., & Tisdale, J. F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004211 · Cited by 20
“Figure 1B illustrates the relative distribution of RIS around the TSS; 49% of the integrations occurred within 10 Kb up- or downstream of TSSs.”
BackgroundTsuruyama, T., Imai, Y., Takeuchi, H., Hiratsuka, T., Maruyama, Y., Kanaya, K., Kaszynski, R. H., Jin, G., Okuno, T., Ozeki, M., et al. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1109748 · Cited by 22
“[11] reported that MLV integration favors transcriptionally active genes.”
BackgroundPerinatal Gene Transfer to the Liver
McKay, T. R., Rahim, A. A., Buckley, S. M. K., Ward, N. J., Chan, J. K. Y., Howe, S. J., & Waddington, S. N. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797247541 · Cited by 20
“For example gammaretroviruses preferentially integrate into the 5’ flanking region of expressed genes near transcription start sites [32], whereas HIV vectors integrate across the whole transcriptional unit.”
BackgroundEnhancer detection in the zebrafish using pseudotyped murine retroviruses.
Laplante, M. A., Kikuta, H., König, M., & Becker, T. S. (2006) · Methods · doi:10.1016/j.ymeth.2006.01.003 · Cited by 21
Antiviral Applications of RNAi
Morris, K. V., & Rossi, J. J. (2006) · Handbook of experimental pharmacology · doi:10.1007/3-540-27262-3_6 · Cited by 23
“Lentiviruses, unlike retroviruses such as Moloney murine leukemia virus (MoMuLV), tend to preferentially integrate downstream of active promoters within the active transcriptional unit, potentially limiting their overall oncogenicity (Wu et al. 2003).”
BackgroundFishing for Answers with Transposons
Wadman, S. A., Clark, K. J., & Hackett, P. B. (2005) · Marine Biotechnology · doi:10.1007/s10126-004-0068-2 · Cited by 20
Robinet, É., Fehse, B., Ebeling, S. B., Sauce, D., Ferrand, C., & Tiberghien, P. (2005) · Cytotherapy · doi:10.1080/14653240510018190 · Cited by 20
Kiem, H., Arumugam, P. I., Burtner, C. R., Fox, C. F., Beard, B. C., Dexheimer, P. J., Adair, J. E., & Malik, P. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.55 · Cited by 20
Vrljicak, P., Tao, S., Varshney, G. K., Quach, H. N. B., Joshi, A., LaFave, M. C., Burgess, S. M., & Sampath, K. (2016) · G3 Genes Genomes Genetics · doi:10.1534/g3.115.026849 · Cited by 19
“MMLV integrations were significantly biased downstream of the TSS, consistent with previous observations in human cells that identified MMLV integrations going into enhancers within the 1st intron (Wu et al. 2003; LaFave et al. 2014).”
BackgroundResultSelf-citationMalhotra, S., Winans, S., Lam, G., Justice, J., Morgan, R. W., & BEEMON, K. L. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006708 · Cited by 22
Potential of transposon-mediated cellular reprogramming towards cell-based therapies
Kumar, D., Anand, T., Talluri, T. R., & Kues, W. A. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i7.527 · Cited by 20
Gene Therapy for Primary Immunodeficiency
Houghton, B. C., & Booth, C. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000509 · Cited by 19
The visual system and paleoecology of the Silurian ostracodPrimitiopsis planifrons
Tanaka, G., Siveter, D. J., & Parker, A. R. (2009) · Journal of Paleontology · doi:10.1666/08-124.1 · Cited by 19
Strauss, B. E., Patrício, J. R., de Carvalho, A. C. V., & Bajgelman, M. C. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.007 · Cited by 21
“Though both virus types can transduce proliferating or post-mitotic cells, lentivirus has the capability of integrating in the host genome, yet the dangers of viral integration are a current topic of scrutiny [34,35].”
BackgroundIdentifying candidate genes involved in brain tumor formation
Swartling, F. J. (2008) · Upsala Journal of Medical Sciences · doi:10.3109/2000-1967-215 · Cited by 20
“This issue was further addressed in a comparative study on murine leukemia virus (165).”
BackgroundGene trap mutagenesis: a functional genomics approach towards reproductive research
Lee, T., Shah, C., & Xu, E. Y. (2007) · Molecular Human Reproduction · doi:10.1093/molehr/gam069 · Cited by 19
“While relatively difficult to manipulate, retroviral gene traps display a preference toward insertion at the 50-end of genes, which is advantageous for generating null alleles (Wu et al., 2003; De-Zolt et al., 2006).”
BackgroundRadiation Drives the Evolution of Orthotopic Xenografts Initiated from Glioblastoma Stem–like Cells
McAbee, J. H., Rath, B. H., Valdez, K., Young, D. L., Wu, X., Shankavaram, U. T., Camphausen, K. A., & Tofilon, P. J. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-2452 · Cited by 20
“Whole Exome Sequencing and Variant Analysis Genomic DNA was subjected to WES, which was performed by the Center for Cancer Research Genomics Technology Laboratory.”
MethodSelf-citationPainter, R. G., Lanson, N. A., Jin, Z., Park, F., & Wang, G. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00085.x · Cited by 19
Molecular mechanisms in allergy and clinical immunology
Shearer, W. T., Rosenwasser, L. J., Bochner, B. S., Gern, J. E., Rosenthal, L. A., Sorkness, R. L., & Lemanske, R. F. (2005) · Cited by 19
Transposon-based vector systems for gene therapy clinical trials: challenges and considerations.
Meir, Y. J., & Wu, S. C. (2011) · PubMed · Cited by 22
Karpov, D. S., Карпов, В. Л., Рафаиловна, К. Р., Demidova, N. A., & Aa, K. (2019) · Molecular Biology · doi:10.1134/s0026898419010051 · Cited by 20
MAEZAWA, M., & INOKUMA, H. (2019) · Archives of Virology · doi:10.1007/s00705-019-04431-6 · Cited by 18
Kitawi, R. C., Ledger, S., Kelleher, A. D., & Ahlenstiel, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052771 · Cited by 24
“…γ retroviruses, for example the murine leukemia virus, preferentially integrate near strong enhancer regions [118], transcriptional start sites [119], CpG islands and DNAse-I hypersensitive sites [120] and can cause insertional mutagenesis when they integrate in the proximity of…”
BackgroundBi, Y., Liu, X., Zhang, L., Shao, C., Ma, Z., Hua, Z., Zhang, L., Li, L., WenJun, H., Xiao, H., et al. (2013) · BMC Molecular Biology · doi:10.1186/1471-2199-14-20 · Cited by 18
“Additionally, this is unlike the integration pattern from virus gene transfer system, such as MLV that shows a strong preference for transcription start sequences [24].”
BackgroundGermline modification of domestic animals.
Tang, L., González, R., & Dobrinski, I. (2015) · PubMed · Cited by 21
Huser, C. A. M., Gilroy, K. L., de Ridder, J., Kilbey, A., Borland, G., Mackay, N. A., Jenkins, A., Bell, M., Herzyk, P., van der Weyden, L., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004167 · Cited by 19
“Further evidence of oncogenic selection: orientation bias and network analysis Preferential integration of c-retroviruses around transcriptional initiation sites is an established phenomenon [19] and on the basis of this and further evidence of non-random behaviour it has been Figure 1.”
BackgroundVector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells
Schambach, A., & Baum, C. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.03.017 · Cited by 21
“Lentiviral vectors as opposed to gammaretroviral vectors are less likely to insert their genetic cargo in the vicinity of cellular promoter sequences [86].”
BackgroundDu, J., Zeng, J., Zhao, Y. H., Boulaire, J., & Wang, S. (2009) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2009.06.017 · Cited by 18
KRAB Can Repress Lentivirus Proviral Transcription Independently of Integration Site
Bulliard, Y., Wiznerowicz, M., Barde, I., & Trono, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602843200 · Cited by 20
Genetic modification of ex-vivo expanded stem cells for clinical application
Aggarwal, R., Pompili, V. J., & Das, H. (2010) · Frontiers in bioscience · doi:10.2741/3650 · Cited by 21
“Evidence indicated that the onco-retroviral integration occurs preferably in the genes that are being actively transcribed in HSCs (89), and some preferred transcription start sites of the HSC genes (90), this can potentially affect the functionality of the HSC upon transplantation (91, 92).”
BackgroundSafety and Stability of Retrovirally Transduced Chimeric Antigen Receptor T Cells
Colovos, C., Villena‐Vargas, J., & Adusumilli, P. S. (2012) · Immunotherapy · doi:10.2217/imt.12.91 · Cited by 18
Viral Hybrid Vectors for Somatic Integration - Are They the Better Solution?
Müther, N., Noske, N., & Ehrhardt, A. (2009) · Viruses · doi:10.3390/v1031295 · Cited by 21
A genome-wide map of adeno-associated virus–mediated human gene targeting
Deyle, D. R., Hansen, R. S., Cornea, A. M., Li, L. B., Burt, A., Alexander, I. E., Sandstrom, R. S., Stamatoyannopoulos, J. A., Wei, C., & Russell, D. W. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2895 · Cited by 18
Giordano, F. A., Hotz‐Wagenblatt, A., Lauterborn, D., Appelt, J. U., Fellenberg, K., Nagy, K. Z., Zeller, W. J., Suhai, S., Früehauf, S., & Laufs, S. (2007) · Methods of Information in Medicine · doi:10.1160/me0423 · Cited by 18
“Several groups have now established molecular biological techniques to determine junctions between viral vectors and human genomic DNA can identify and receive large numbers of insertion sites [5-8].”
BackgroundMaddison, L. A., Lu, J., Victoroff, T. M., Scott, E. K., Baier, H., & Chen, W. (2009) · Molecular Genetics and Genomics · doi:10.1007/s00438-009-0428-8 · Cited by 18
“As has been highlighted by others (Wu et al. 2003; Wang et al. 2007) and further supported by this work, the MMLV mediated viral integrations that occur within genes are primarily at the 5 end of the gene.”
BackgroundInfluentialSymmetrical recognition of cellular DNA target sequences during retroviral integration
Grandgenett, D. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502045102 · Cited by 18
Ambrosi, A., Cattoglio, C., & Serio, C. D. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000144 · Cited by 18
“Starting from a common annotation criteria [2,7,12,13], we focus on ID from the TSS of the nearest 39 or 59 end of a gene (which might differ from the ID from the nearest TSS).”
MethodNielsen, A. A., Sørensen, A. B., Schmidt, J., & Pedersen, F. S. (2004) · Journal of Virology · doi:10.1128/jvi.79.1.67-78.2005 · Cited by 19
“In contrast to the retrovirus-like Ty retrotransposons in yeast, which are very selective in the choice of integration sites (as reviewed in reference 9), retroviruses integrate throughout the chromosomes (10, 22, 33, 37, 42, 43, 46, 49, 50, 63, 65, 67, 70, 75, 76).”
Progress in the Therapeutic Applications of siRNAs Against HIV-1
Martínez, M. Á. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-547-7_17 · Cited by 19
“One of the main concerns with current gene therapy approaches is insertional mutagenesis from preferential integration of retroviral vectors into actively transcribed genes, including proto-oncogenes.”
BackgroundAdvances and Challenges in the Development of Gene Therapy Medicinal Products for Rare Diseases
Bueren, J. A., & Auricchio, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.152 · Cited by 17
“13 15–17”
Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells
Doering, C. B., Archer, D. R., & Spencer, H. T. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.005 · Cited by 18
“It is now known that γ –retroviruses integrate into chromosomal sites of active transcription [18–22].”
BackgroundMultifunctional facets of retrovirus integrase
Grandgenett, D. P., Pandey, K. K., Bera, S., & Aihara, H. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i3.83 · Cited by 23
Retroviral vector interactions with hematopoietic cells
Everson, E. M., & Trobridge, G. D. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.07.010 · Cited by 19
Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis
Biasco, L., Rothe, M., Schott, J. W., & Schambach, A. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.009 · Cited by 19
Effects of Lentivirus-Mediated C3 Expression on Trabecular Meshwork Cells and Intraocular Pressure
Tan, J., Fan, N., Wang, N., Feng, B.-K., Yang, M., Liu, G., Wang, Y., Zhu, X., Kaufman, P. L., Pang, I.-H., et al. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24978 · Cited by 17
“The type C-retrovirus cannot be used to transduce nondividing cells(20) and appears to be oncogenic.(21) The AAV vectors usually show lower immunogenicity and persistent expression(22,23) and have been used in inherited disease studies, especially retinal and optic nerve diseases.”
BackgroundDefining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
El-Akabawy, N., Rodriguez, M., Ramamurthy, R. M., Rabah, A., Trevisan, B., Morsi, A., George, S. K., Shields, J. E., Meares, D., Farland, A. M., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.001 · Cited by 18
Viral Hijacking of BET Proteins
Chen, I. P., & Ott, M. (2022) · Viruses · doi:10.3390/v14102274 · Cited by 18
D’Apolito, D., Baiamonte, E., Bagliesi, M., Marzo, R. D., Calzolari, R., Ferro, L., Franco, V., Spinelli, G., Maggio, A., & Acuto, S. (2009) · Molecular Therapy · doi:10.1038/mt.2009.74 · Cited by 17
Exceptionally preserved ostracodes from a Middle Miocene palaeolake, California, USA
Wilkinson, I. P., Wilby, P. R., Williams, M., Siveter, D. J., Page, A. A., Leggitt, L., & Riley, D. A. (2010) · Journal of the Geological Society · doi:10.1144/0016-76492009-178 · Cited by 17
Kumar, P. P., Mehta, S. S., Purbey, P. K., Notani, D., Jayani, R. S., Purohit, H. J., Raje, D. V., Ravi, D. S., Bhonde, R. R., Mitra, D., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01405-06 · Cited by 18
“Additionally, HIV integrations favor the entire length of the transcriptional regions whereas MLV integrations are distributed evenly upstream and downstream of the transcriptional start site (53).”
BackgroundInfluentialRegulation of Foamy Viral Transcription and RNA Export
Bodem, J. (2011) · Advances in virus research · doi:10.1016/b978-0-12-385885-6.00006-7 · Cited by 17
Nash, K. L., Alexander, G., & Lever, A. M. L. (2005) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2005.00612.x · Cited by 17
Plachý, J., Kotáb, J., Divina, P., Reinišová, M., Šenigl, F., & Hejnar, J. (2010) · Journal of Virology · doi:10.1128/jvi.02511-09 · Cited by 17
“Uniquely, murine leukemia virus (MLV) favors integration in close proximity to upstream or downstream transcription start sites (48).”
BackgroundLabrador, M., Sha, K., Li, A., & Corces, V. G. (2008) · Genetics · doi:10.1534/genetics.108.094318 · Cited by 17
“For example, both HIV and murine leukemia virus (MLV) integrate in actively transcribing DNA, but HIV integrates with equal fre- quency throughout all transcribed DNA, whereas MLV integrates preferentially into transcription start sites (Schroder et al. 2002; Wu et al. 2003).”
BackgroundBao, L., Jaligam, V. R., Zhang, X., Kutner, R. H., Kantrow, S. P., & Reiser, J. (2004) · Human Gene Therapy · doi:10.1089/10430340460745775 · Cited by 18
“They are unique for each DNA sample because HIV-1 integrates into the host cell genome with limited site preference (Schroder et al ., 2002; Wu et al ., 2003).”
Gene therapy for immune disorders: Good news tempered by bad news
Puck, J. M., & Malech, H. L. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.041 · Cited by 17
Retroviral integration profiles: their determinants and implications for gene therapy
Lim, K. (2012) · BMB Reports · doi:10.5483/bmbrep.2012.45.4.207 · Cited by 17
“binding sites (TFBSs) (22) and moderately genes, especially highly expressed genes, during integration (16, 21).”
BackgroundNasimuzzaman, M., Kim, Y., Wang, Y., & Persons, D. A. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.20 · Cited by 16
Gene Therapy - Developments and Future Perspectives
Kang, C. (2011) · InTech eBooks · doi:10.5772/748 · Cited by 16
Genetic Strategies for HIV Treatment and Prevention
Falkenhagen, A., & Joshi, S. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.018 · Cited by 17
Loew, R., Vigna, E., Lindemann, D., Luigi, N., & Bujard, H. (2006) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000021 · Cited by 17
“At this point, it is important to consider that MuLV-based retroviral vectors seem to preferably integrate into or close to transcriptional start sites of human cellular promoters ( Wu et al, 2003; Nowrouzi et al, 2006), thus in many cases will expose the minimal promoters to unfavorable environment were enhancers but…”
BackgroundHuston, M. W., Brugman, M. H., Horsman, S., Stubbs, A., van der Spek, P. J., & Wagemaker, G. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.037 · Cited by 18
“In general, we suggest that the nearest gene be whichever gene has its 5’ end closest to the IS, as viral integrations are known to alter expression of nearby genes via the long-terminal repeats (Wu et al. , 2003; Lewinski et al. , 2006) or the internal promoters (Modlich et al. , 2009).”
Gabriel, R., Kutschera, I., Bartholomae, C. C., Kalle, C. V., & Schmidt, M. (2014) · Journal of Visualized Experiments · doi:10.3791/51543 · Cited by 21
Enhanced T cell receptor gene therapy for cancer
Kieback, E., & Uckert, W. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003689998 · Cited by 20
“It is now known that insertion of these vectors into the host genome occurs preferentially into transcriptionally active sites [99-101] and adverse events due to oncogenic transformation have been reported in otherwise successful clinical trials of gene therapy for X-linked severe combined immunodeficiency [102].”
BackgroundFunctional therapies for cutaneous wound repair in epidermolysis bullosa
Peking, P., Koller, U., & Murauer, E. M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.12.003 · Cited by 19
Retroviral Integration Sites Correlate with Expressed Genes in Hematopoietic Stem Cells
Wagner, W., Laufs, S., Blake, J., Schwager, C., Wu, X., Zeller, J. W., Ho, A. D., & Früehauf, S. (2005) · Stem Cells · doi:10.1634/stemcells.2005-0006 · Cited by 16
Self-citationBeard, B. C., Mezquita, P., Morris, J. C., & Kiem, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.016 · Cited by 16
Versatility of gene therapy vectors through viruses
Barzon, L., Stefani, A., Pacenti, M., & Palù, G. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.5.639 · Cited by 19
“Mapping of > 900 MLV integration sites in the human genome showed that 34% of MLV integrations landed in genes [97], a frequency lower than that observed in HIV-1-infected cells, where ∼ 60% of HIV-1 integrations involved genes [97,107].”
BackgroundGene Therapy for Primary Immunodeficiencies
Fischer, A., Hacein‐Bey‐Abina, S., & Cavazzana, M. (2010) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2010.02.002 · Cited by 20
HIV Latency: Present Knowledge and Future Directions
Contreras, X., Lenasi, T., & Peterlin, B. M. (2006) · Future Virology · doi:10.2217/17460794.1.6.733 · Cited by 20
“Three studies where T cells were infected without selection in vitro also demonstrated the integration into actively transcribed genes [16–18].”
BackgroundThe N-Terminus of Murine Leukaemia Virus p12 Protein Is Required for Mature Core Stability
Wight, D. J., Boucherit, V., Wanaguru, M., Elis, E., Hirst, E. M. A., Li, W., Ehrlich, M., Bacharach, E., & Bishop, K. N. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004474 · Cited by 16
Montaño, S. P., Coté, M. L., Roth, M. J., & Georgiadis, M. M. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl693 · Cited by 15
Advances of gene therapy for primary immunodeficiencies
Candotti, F. (2016) · F1000Research · doi:10.12688/f1000research.7512.1 · Cited by 17
“…vectors for gene therapy of SCIDX-1 and other PIDs, investigators turned to gene transfer constructs based on human immunodeficiency virus type 1 (HIV-1) that are accepted as integrating vectors with lower potential to cause activation of oncogenes located near their genomic integration sites 21 .”
BackgroundWen, Y., Liao, G., Pritchard, T., Zhao, T., Connelly, J. P., Pruett‐Miller, S. M., Blanc, V., Davidson, N. O., & Madison, B. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.777722 · Cited by 19
Wang, Z., Troilo, P. J., Griffiths, T. G., Harper, L. B., Barnum, A. B., Pacchione, S. J., Pauley, C. J., Lebron, J. A., Wolf, J. J., & Ledwith, B. J. (2021) · Gene Therapy · doi:10.1038/s41434-021-00278-2 · Cited by 15
Improving TCR Gene Therapy for Treatment of Haematological Malignancies
Nicholson, E., Ghorashian, S., & Stauss, H. J. (2012) · Advances in Hematology · doi:10.1155/2012/404081 · Cited by 18
“Insertions of viral LTR at these points will have a higher probability of causing aberrant gene expression [104, 105].”
BackgroundKawabe, Y., Shimomura, T., Huang, S., Imanishi, S., Itô, A., & Kamihira, M. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25923 · Cited by 16
“However, retroviral transgene integration occurs approximately at random in the host cell genome, although integration preference has been reported (Wu et al., 2003).”
BackgroundEngineering mutations: Deconstructing the mouse gene by gene
Raymond, C. S., & Soriano, P. M. (2006) · Developmental Dynamics · doi:10.1002/dvdy.20845 · Cited by 18
“This insertion site preference may be due to an open chromatin configuration of the DNA in this region that facilitates retroviral integration (Wu et al., 2003).”
BackgroundMcAllister, R. G., Liu, J., Woods, M. W., Tom, S. K., Rupar, C. A., & Barr, S. D. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.39 · Cited by 17
Pulè, M. A., Rousseau, A., Vera, J. F., Heslop, H., Brenner, M. K., & Vanin, E. F. (2008) · Cytotherapy · doi:10.1080/14653240802192636 · Cited by 15
“As integration is semirandom [6-9], each integration site generates a unique integrant–host–junction (IHJ) that can be used as a marker to study clonal evolution of engrafted cells or analyze potentially oncogenic insertional mutagenesis [10-12].”
BackgroundAn Alternative Method for the Rapid Generation of Stable, High-Expressing Mammalian Cell Lines
Bleck, G. T. (2006) · BioProcessing Journal · doi:10.12665/j54.bleck · Cited by 15
Braun, S. E., Wong, F. E., Connole, M., Qiu, G., Lee, L., Gillis, J., Lü, X., Humeau, L. M. P. F., Slepushkin, V., Binder, G. K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.698 · Cited by 15
Lenti in red: progress in gene therapy for human hemoglobinopathies
Kalle, C. V., Baum, C., & Williams, D. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci23132 · Cited by 16
“broader context, MLV-based vectors show a preference for insertions in promoter-proximal regions of active genes (8).”
BackgroundSerhan, F., Penaud‐Budloo, M., Petit, C., Lesté-Lasserre, T., Trajcevski, S., Klatzmann, D., Duisit, G., Sonigo, P., & Moullier, P. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6190-6199.2004 · Cited by 15
“During and after mitosis, the PIC penetrates the nuclear compartment and the viral DNA integrates, as recently shown, into the human host cell genome near the start of transcriptional units (48).”
BackgroundHu, J., Ferris, A. L., Larochelle, A., Krouse, A. E., Metzger, M. E., Donahue, R. E., Hughes, S. H., & Dunbar, C. E. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.175 · Cited by 18
“…to transcription start sites of genes and that human immunodeficiency virus (HIV)- or simian immunodeficiency virus (SIV)-derived lentiviral vectors strongly favor integration within genes, particularly highly expressed genes (Schroder et al. , 2002; Wu et al. , 2003; Hematti et al. , 2004).”
Blomberg, J., Sheikholvaezin, A., Elfaitouri, A., Blomberg, F., Sjösten, A., Mattsson, J. U., Pipkorn, R., Källander, C. F. R., Öhrmalm, C., & Sperber, G. (2011) · Advances in Virology · doi:10.1155/2011/341294 · Cited by 16
“The propensity to integrate into or next to promoters is a gammaretroviral specialty [36–38].”
BackgroundIntegration Site Analysis in Gene Therapy Patients: Expectations and Reality
Biasco, L. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.183 · Cited by 17
“4,5 As a consequence, the permanent gene transfer achieved by integrating vectors comes with a potential risk of altering the cell’s natural genetic program due to the disruption of tumor suppressor genes, to the generation of new gene isoforms (from aberrant splicing or premature termination of…”
Papanikolaou, E., Paruzynski, A., Kasampalidis, I. N., Deichmann, A., Stamateris, E., Schmidt, M., Kalle, C. V., & Anagnou, N. P. (2014) · Molecular Therapy · doi:10.1038/mt.2014.246 · Cited by 14
Chromosomal tethering and proviral integration
Delelis, O., Zamborlini, A., Thierry, S., & Saïb, A. (2009) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.08.005 · Cited by 15
Dunbar, C. E. (2007) · Hematology · doi:10.1182/asheducation-2007.1.460 · Cited by 14
“Human immunodeficiency virus (HIV) and HIV vectors preferentially integrated into actively expressed genes in T-cell lines, and MLV vectors preferentially integrated near the 5′ transcription start sites of genes in fibroblast cell lines.(18,19) These patterns would be predicted to increase the risk of perturbation of…”
BackgroundPolybutylcyanoacrylate nanoparticles as novel vectors in cancer gene therapy
Zhang, Y., Zhang, Y., Chen, J., Zhang, B., Pan, Y., Ren, L., Zhao, J., Luo, Y., Zhai, D., Wang, S., et al. (2007) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2007.01.004 · Cited by 14
“Many reports have confirmed that the HSV-TK/GCV system could induce apoptosis of tumor cells [19,20], and this is related to the expression of p53 gene in cells and upregulation of expression of Fas/FasL [21-26].”
BackgroundInteractions of Host Proteins with the Murine Leukemia Virus Integrase
Studamire, B., & Goff, S. P. (2010) · Viruses · doi:10.3390/v2051110 · Cited by 14
“The same study also analyzed wild type and pseudotyped HIV-1 in human H9 cells and HeLa cells, respectively, and found that HIV-1 integration was favored in the transcribed regions of genes [59].”
BackgroundMiklík, D., Šenigl, F., & Hejnar, J. (2018) · Viruses · doi:10.3390/v10030116 · Cited by 17
“Human immunodeficiency virus type 1 (HIV) and related lentiviruses preferentially integrate into active genes [2–6] whereas murine leukaemia virus (MLV) and other gammaretroviruses prefer to integrate into active transcriptional start sites (TSS) and enhancers [4,5,7].”
BackgroundReducing the Genotoxic Potential of Retroviral Vectors
Ramezani, A., Hawley, T. S., & Hawley, R. G. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-248-3_12 · Cited by 15
“Rather, they preferentially insert their cargos into open chromatin regions in close proximity to or within genes (6,17,18).”
BackgroundWang, Y., Wang, Y.-H., Zhao, G.-Q., & Li, Y. (2011) · PubMed · Cited by 16
Self-citationBester, A. C., Kafri, M., Maoz, K., & Kerem, B. (2013) · Scientific Reports · doi:10.1038/srep02189 · Cited by 15
Metadata
- Authors
- Wu, X., Li, Y., Crise, B., & Burgess, S. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Burgess, Shawn M.
- Venue
- Science
- Published
- 2003-06-13
- Volume
- 300
- Issue
- 5626
- Pages
- 1749-1751
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1637867377
- Cited by
- 1,305
- References
- 18
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 25 · 2020: 27 · 2019: 33 · 2018: 24 · 2017: 39 · 2016: 43 · 2015: 49 · 2014: 65 · 2013: 51 · 2012: 83
- FWCI
- 57.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01co12400-79-0-22)
- National Cancer Institute (N01CO12400)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Chromosomal and Genetic Variations
- Keywords
- retroviral integration, transcription start sites, murine leukemia virus, HIV-1, human genome, gene therapy
- MeSH terms
- Child, Genetic Vectors, HeLa Cells, Humans, Leukemia, Leukemia Virus, Murine, Promoter Regions, Genetic, Transcription, Genetic, Tumor Cells, Cultured, Genetic Therapy, HIV-1, Gene Expression, Genome, Human, Virus Integration, CpG Islands, Oligonucleotide Array Sequence Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.